AlloVirNASDAQ: ALVR

MILWAUKEE--(BUSINESS WIRE)--Ademi LLP is investigating AlloVir (Nasdaq: ALVR) for possible breaches of fiduciary duty and other violations of law in its transaction with Kalaris. Click here to learn how to join our investigation and obtain additional information or contact us at [email protected] or toll-free: 866-264-3995. There is no cost or obligation to you. In the transaction, stockholders of AlloVir will own only approximately 25.05% of the combined company and pre-Merger Kalaris stockh.

Kalaris is a clinical-stage biopharmaceutical company founded by Samsara BioCapital and focused on development of TH103, a novel, differentiated and potentially transformative therapy for patients with neovascular and exudative retinal diseases

NEW YORK, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating AlloVir , Inc. (NASDAQ: ALVR ), relating to its proposed merger with Kalaris Therapeutics. Under the terms of the agreement, AlloVir will acquire 100% of the outstanding equity interest of Kalaris. Upon completion of the Merger, pre-Merger AlloVir stockholders are expected to own approximately 25.05% of the combined company and pre-Merger Kalaris stockholders are expected to own approximately 74.95% of the combined company.

NEW YORK, Sept. 16, 2024 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of AlloVir, Inc. (NASDAQ: ALVR) breached their fiduciary duties to shareholders.

Here is how AlloVir, Inc. (ALVR) and Arcutis Biotherapeutics, Inc. (ARQT) have performed compared to their sector so far this year.

AlloVir, Inc. (ALVR) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

AlloVir (NASDAQ: ALVR ) layoffs are in the news as the clinical-stage cell therapy company announced a massive number of job cuts. AlloVir has revealed that a new round of layoffs will have it cutting 95% of its workforce.

AlloVir Inc. ALVR, +5.02%, a developer of cell therapies intended to treat viral diseases, said Thursday that its board had approved a roughly 95% reduction to its staff, following an announcement last month that it would discontinue three clinical trials on its lead T cell therapy posoleucel. The company, in a filing, said the board approved the cuts on Jan. 1, and that the cuts were intended to “preserve capital.

Shares of AlloVir Inc. ALVR, -66.75% plummeted 66.6% toward their first-ever close below $1 on heavy volume in afternoon trading Friday, after the immunotherapy company decided to discontinue the Phase 3 trials on posoleucel, a T cell therapy targeting a number of pathogens in immunocompromised people, citing “futility.” The stock, which was the biggest decliner among those listed on major U.S. exchanges, is headed for its biggest decline since going public in July 2020.